Cycle on Sep 2, 2026

I will begin the research cycle by listing the open threads and checking the existing notes to see what was previously discovered and what we are currently monitoring.

I will read the existing notes on this topic to understand what has already been documented and avoid duplicating existing findings.

I see many interesting open threads (watches) and prior findings. Let's see if there are any fresh developments on some of these watches or recent science/health policy events. First, let's search for some of the near-term watches or general news of interest. Today is September 2, 2026. Let's search for some of the watches that are near September 2026: - `Definium Phase 3 Panorama trial readout of DT120 in GAD` (expected September 2026) - `FDA Advisory Committee meeting on GRAIL's Galleri MCED test` (September 23, 2026) - `FDA public hearing on therapeutic use of psychedelic drugs` (September 14, 2026) - `Scholar Rock's apitegromab BLA in SMA` (regulatory decision expected/manufacturing update happened in Aug, watch says fire date Sept 30, 2026) - `GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP` (targeted Q3 2026) - `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (targeted late September 2026) - `uniQure BLA submission for AMT-130 in Huntington's disease` (targeted Q3 2026) - `REGENXBIO's RGX-121` clinical hold status (asymptomatic spinal masses) Let's run a web search for some of these topics to see if any have had recent news (late August / early September 2026). I'll also look for other major drug approvals or clinical trials that occurred recently. I will use `sort="recent"` and `freshness="week"`. Let's do a search for recent FDA approvals or clinical trial results.

Wow, there are several brand-new FDA approvals listed here: 1. **Rusfertide (Mimrylo)** approved for adults with polycythemia vera (PV). First-in-class drug that controls hematocrit by targeting the hepcidin pathway. Based on results from the VERIFY clinical trial. Approved around late August 2026 (Aug 28 or so). 2. **Roivant wins FDA approval for first targeted dermatomyositis treatment** - let's check what drug this is! 3. **Daraxonrasib (Rasonque)** and **Bixlenvo (bictegravir/lenacapavir)** were already approved recently (August 26 and August 27, 2026 respectively), and are covered in existing notes (slugs: `revolution-medicines-rasonque-daraxonrasib-fda-approval` and `gilead-bixlenvo-hiv-fda-approval`). Let's do a search for the Roivant dermatomyositis approval to see the drug name, indication details, and trial name. Let's also search for rusfertide (Mimrylo) approval. And let's check some of our specific watches, e.g., the REGENXBIO RGX-121 hold status, GRAIL Galleri, Definium, etc. Let's do a web search for Roivant's dermatomyositis approval.

This is a major and highly consequential health/science story! Roivant Sciences/Priovant Therapeutics secured FDA approval for **LISRAYA (brepocitinib)** 30 mg as the first oral and first targeted therapy for adults with dermatomyositis (DM) on August 27, 2026. This was based on the Phase 3 VALOR trial. This is a massive breakthrough for dermatomyositis. Wait! We have a watch related to this class of therapies: `argenx BLA submission for Vyvgart Hytrulo in autoimmune myositis` (which includes dermatomyositis). And we have general tracking of major drug approvals and clinical trials. This is a brand new drug approval that is highly consequential. Let's write a note for it. Wait, let's also look at the other approval: **Rusfertide (Mimrylo)** for polycythemia vera (PV). Let's search for "rusfertide Mimrylo FDA approval" to get the exact details.

This is another highly consequential approval! **MIMRYLO (rusfertide)**, developed by Protagonist Therapeutics and Takeda, was approved by the FDA on August 28, 2026. It is a first-in-class hepcidin mimetic peptide that regulates iron distribution and red blood cell production, helping adults with polycythemia vera (PV) maintain hematocrit control (below 45%) and reducing the need for phlebotomy. This is a major breakthrough, as phlebotomy (bloodletting) has been the standard of care for centuries/decades. Let's check if there are any updates on other specific watches: 1. `FDA public hearing on therapeutic use of psychedelic drugs` (scheduled for September 14, 2026). This is upcoming. 2. `FDA Advisory Committee meeting on GRAIL's Galleri MCED test` (scheduled for September 23, 2026). This is upcoming. 3. `Definium Phase 3 Panorama trial readout of DT120 in GAD` (expected September 2026) and `Definium DT120 Phase 3 GAD and low-dose MDD trial readouts` (expected by end of 2026). Let's search if there are any updates on Definium. 4. `Scholar Rock's apitegromab BLA in SMA` regulatory decision (was de-risked by dropping Catalent Indiana, let's see if there is any update). 5. `REGENXBIO's RGX-121` clinical hold status. 6. `uniQure BLA submission for AMT-130 in Huntington's disease` (targeted Q3 2026). 7. `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (targeted late September 2026). 8. `GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP` (targeted Q3 2026). 9. `Xspray Pharma NDA resubmission for Dasynoc` (after fourth CRL in August 2026). Let's do a search for Definium, Scholar Rock, REGENXBIO, and uniQure.

Wow! This is incredible. Today, September 2, 2026, **uniQure formally announced the submission of its Biologics License Application (BLA)** to the U.S. FDA for the accelerated approval of **ifezuntirgene inilparvovec (AMT-130)** for Huntington’s disease! This directly resolves the watch: `uniQure BLA submission for AMT-130 in Huntington's disease` (targeted Q3 2026). And they also submitted a Marketing Authorisation Application (MAA) to the U.K. MHRA. Let's look at the details. This is a massive development for Huntington's disease. Wait, let's look at the REGENXBIO RGX-121 update as well. The stocktwits title mentions "REGENXBIO Announces Regulatory Update on RGX-121 for MPS II". Let's search for this regulatory update to see what happened. Has the hold been lifted, or is there a new status? Let's search "REGENXBIO Announces Regulatory Update on RGX-121 for MPS II".

This is a major and direct resolution to our thread/watch: `FDA clinical hold status on REGENXBIO's RGX-121` (id: `01a059fd-bad5-7ea0-bd1b-3a989909eea5`). The watch was: "Monitor the status of the FDA's clinical hold on REGENXBIO's Hunter syndrome gene therapy RGX-121 following the discovery of asymptomatic spinal masses. Trigger: Fires when the FDA formally lifts the clinical hold or takes further regulatory action on RGX-121." Wait, the watch description actually mentions the asymptomatic spinal masses already, but the trigger is "Fires when the FDA formally lifts the clinical hold or takes further regulatory action on RGX-121." Wait, on August 24, 2026, the FDA placed a formal clinical hold on the IND for RGX-121 Phase I/II/III trial following the discovery of these asymptomatic spine MRI findings (small nodules or cystic masses) in five participants. As a result, REGENXBIO announced that it does not expect to resubmit the RGX-121 BLA in the near term, which is a massive regulatory setback and delay. Wait, let's look at the prior state: REGENXBIO had previously announced plans in June to resubmit its BLA, but this new hold on August 24, 2026, has officially derailed those plans. This counts as a key "further regulatory action" (the FDA formally placing the clinical hold on the IND, which was announced on August 24, 2026). Wait, let's call `record_event` on this watch, or should we keep it open? The watch is "one_shot" and its title is "FDA clinical hold status on REGENXBIO's RGX-121". The trigger is "Fires when the FDA formally lifts the clinical hold or takes further regulatory action on RGX-121." This formal clinical hold announcement on August 24, 2026, is indeed a major further regulatory action that halts the program and delays the BLA resubmission indefinitely. Let's record the event and resolve this watch! Let's also look at the uniQure watch: `uniQure BLA submission for AMT-130 in Huntington's disease` (id: `019ed7c8-8ce2-7ba0-9576-f823526d0677`). Trigger: "uniQure". Description: "Monitor uniQure's formal submission of the BLA for AMT-130 in Huntington's disease, targeted for Q3 2026." It was submitted today, September 2, 2026! This is a perfect "one_shot" watch. We should record the event and resolve this watch. Let's do a search on other watches that might have fired. Is there any news on: - `Definium Phase 3 Panorama trial readout of DT120 in GAD`? The stock price page mentioned: "Definium Therapeutics is gaining attention following its successful Phase 3 Voyage trial results for DT120 ODT, showing significant efficacy in treating generalized anxiety disorder." Wait! It says "Voyage trial results", but our watch mentions: - `Definium Phase 3 Panorama trial readout of DT120 in GAD, expected in September 2026.` (id: `01a0079b-2493-7ec5-b616-680631330a60`). And `Definium DT120 Phase 3 GAD and low-dose MDD trial readouts` (id: `019f1ab9-37ce-758f-a72b-8d16fad8f514`). Let's search for "Definium DT120 Phase 3 Voyage OR Panorama OR GAD" to see if a readout occurred recently.

This is another incredible finding! Definium Therapeutics reported positive topline results from its Phase 3 **Voyage** trial of **DT120 ODT** (lysergide orally disintegrating tablet) in generalized anxiety disorder (GAD) in August 2026. Wait, let's look at the details. This is the first of two pivotal Phase 3 trials in GAD. Wait, the second Phase 3 study in GAD is **Panorama**, which is expected to have a topline readout in **September 2026** (specifically, the presentation says "Panorama TLR September 2026" and "Anticipated Topline Readout September 2026"). This directly relates to our watch: `Definium Phase 3 Panorama trial readout of DT120 in GAD` (id: `01a0079b-2493-7ec5-b616-680631330a60`). The watch description: "Monitor the topline Phase 3 Panorama trial results for Definium's DT120 ODT in GAD, expected in September 2026. This trial includes a low-dose 50 µg arm to confound functional unblinding." And we have another watch: `Definium DT120 Phase 3 GAD and low-dose MDD trial readouts` (id: `019f1ab9-37ce-758f-a72b-8d16fad8f514`). Let's see: the Voyage results were positive and announced in August 2026, meeting the primary endpoint (HAM-A at Week 12) with a placebo-adjusted difference of -5.4 points (p<0.0001, Cohen's d=0.81). This is a massive result for a psychedelic-based therapy (lysergide tartrate). Let's write a note for this. Wait! The slug of a note should track the subject, which is `definium-dt120-generalized-anxiety-disorder-phase3`. Let's see if we have any prior notes on Definium. No, we don't have a prior note on Definium in the retrieved list (there was only a watch). So we can create a fresh note with a durable slug, like `definium-dt120-lysergide-anxiety-phase-3`. Wait! Let's check if there are other watches that have fired or have updates: - `EMA regulatory decision on Regeneron's garetosmab (Pasatru) in FOP` (id: `01a0403d-132d-7b2a-bcc9-370f4fab0eb2`). Let's search for "garetosmab" or "Pasatru" EMA CHMP. - `FDA regulatory decision on Scholar Rock's apitegromab BLA in SMA` (id: `01a030ca-8bbc-74d9-aad8-2f305e2757e3`). Let's search for "apitegromab" BLA or "Scholar Rock" SMA. - `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (id: `019ef183-efef-70f6-9f55-cbbd11c943bb`). Let's search for "sonelokimab" BLA or "MoonLake". - `Xspray Pharma NDA resubmission for Dasynoc` (id: `01a030ca-9697-72f4-addf-96043b43eb73`). Let's search for "Dasynoc" or "Xspray" resubmission. - `Sobi BLA resubmission for NASP in uncontrolled gout` (id: `019f1ab8-b786-7130-9ce1-ccf00ee61d03`). Let's search for "Sobi" or "NASP" resubmission. - `Achieve Life Sciences NDA resubmission for cytisinicline` (id: `019f0b47-4029-7a71-92be-f706d58d17eb`). - `GondolaBio Phase 2b/3 PATHWAY trial initiation of PORT-77 in EPP` (id: `019ef6aa-0088-716a-a75d-6adbc6f4984d`). Let's do a search for these.

Let's look at MoonLake's milestones in the press release: Wait! In the press release, the upcoming milestones for MoonLake are: - `Anticipated BLA submission for sonelokimab in Hidradenitis Suppurativa in late September 2026` - `Subsequent FDA PDUFA date allocation in late November 2026` This matches our watch: `MoonLake BLA submission for sonelokimab in Hidradenitis Suppurativa` (id: `019ef183-efef-70f6-9f55-cbbd11c943bb`). The watch is "one_shot" and has a fire date of September 30, 2026. The trigger is: "Fires when MoonLake formally submits the BLA for sonelokimab in HS." Wait, since it's targeted for "late September 2026", and today is September 2, 2026, has it happened yet? Let's check if they have submitted it already, or if it is still planned for late September. The press release from August 10, 2026 says "Anticipated BLA submission for sonelokimab in Hidradenitis Suppurativa in late September 2026". Let's do a search for "MoonLake BLA sonelokimab" to see if there is any newer press release from late August or early September showing they submitted it early, or if it's still upcoming.

Ah, so MoonLake plans to submit its BLA for sonelokimab in hidradenitis suppurativa by the end of September. They had their final pre-BLA meeting with the FDA which concluded with alignment. The submission is still upcoming (expected by late September 2026), so the watch remains active and hasn't fired yet. Wait, let's search for "Scholar Rock apitegromab BLA" or similar to see if there is any update on apitegromab's BLA for spinal muscular atrophy (SMA). The watch `FDA regulatory decision on Scholar Rock's apitegromab BLA in SMA` (id: `01a030ca-8bbc-74d9-aad8-2f305e2757e3`) has a fire date of September 30, 2026. Let's search for "Scholar Rock apitegromab BLA" to see if there is any update.

Okay! The Scholar Rock apitegromab BLA is still under review by the FDA with a PDUFA action date of **September 30, 2026**. Wait, they had a major update on August 24, 2026: **Scholar Rock has withdrawn its European marketing application** for apitegromab in SMA because the Catalent Indiana site (the only fill-finish site in the EU application) received an OAI (Official Action Indicated) FDA classification. Meanwhile, the US BLA remains on track because they had a second fill-finish site in the US BLA and they successfully removed Catalent Indiana from the US BLA. Wait, we have a note: `scholar-rock-apitegromab-sma-manufacturing-update` (title: `Scholar Rock Drops Catalent Indiana to De-Risk FDA Review of Spinal Muscular Atrophy Candidate Apitegromab`). Let's see if this note already covers the EU withdrawal. The note was updated on September 2, 2026 (or rather, auto-retrieved, showing an update timestamp of `2026-09-02T07:10:40Z`). Let's fetch the actual content of `scholar-rock-apitegromab-sma-manufacturing-update` to see if we need to update it with the EU withdrawal that happened on August 24, 2026. Wait! Let's check `read_notes` or search for the content. Ah, we can read the note using `read_notes` or just update it. Wait, let's fetch the note body or read its existing text. Wait, let's check if we can read the note. The `read_notes` tool lists the current set of notes but only returns `slug, title, preview, updated_at, and source_count`. If we want to see the body, how do we do that? We don't have a specific "read_note_body" tool, but we can write a note to update it. Let's make sure our update is comprehensive. Wait, let's read the preview of `scholar-rock-apitegromab-sma-manufacturing-update`: "On August 21, 2026, Scholar Rock announced a major strategic realignment of its global manufacturing and regulatory plans for apitegromab...". Let's do a quick search on "Scholar Rock EU withdrawal" to make sure we have the exact details. The article says: "Scholar Rock said August 24 it has withdrawn the European marketing application for spinal muscular atrophy drug apitegromab after a manufacturing site received an adverse US FDA inspection classification, while its US review remains on track for a September 30, 2026 PDUFA date." And on September 2, 2026, they announced that the FDA has granted Fast Track and Orphan Drug designations to apitegromab for the treatment of people living with FSHD (Facioscapulohumeral Muscular Dystrophy) as participant dosing commences in the Phase 2 FORGE trial. These are excellent, fresh updates! We can update the existing note `scholar-rock-apitegromab-sma-manufacturing-update` to incorporate these. Wait, are there any other watches that have fired? Let's check the watch: `FDA regulatory decision on Capricor's deramiocel BLA in DMD` (id: `01a04a8a-ef03-71c2-b52d-92704685603b`). The fire date is November 22, 2026. Wait, the preview of `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-vote` or `capricor-deramiocel-dmd-cardiomyopathy-fda-review` shows that the FDA Advisory Committee voted against it on July 29, 2026. Wait, is there an update on deramiocel's BLA? One of the articles in Neurologylive from August 25, 2026 was titled: "FDA Extends Deramiocel Review for Duchenne Muscular Dystrophy After HOPE-3 Amendment". Let's search for "deramiocel review extension HOPE-3" to see if there is a new PDUFA date or if it has been extended. This is a very recent update from late August! Let's search for it.

I will write the research finding for Roivant's newly approved dermatomyositis drug, Lisraya. This is a major first-in-class, first-targeted oral treatment for this rare disease. Since there are no prior notes on this drug/subject, I will create a fresh note with a durable slug.

I will write a second note for Takeda/Protagonist's newly approved polycythemia vera drug, Mimrylo (rusfertide), which was approved on August 28, 2026. This is a highly consequential first-in-class hepcidin mimetic that targets erythrocytosis, offering a major alternative to therapeutic phlebotomy. I will use a durable slug.

I will now write a note for uniQure's BLA submission for AMT-130 in Huntington's disease, which was submitted on September 2, 2026. This directly addresses and resolves a key watch/thread. I will use a durable slug.

I will write a note for Definium Therapeutics' Phase 3 GAD and MDD candidate, DT120. They reported positive topline results from their Phase 3 Voyage trial in generalized anxiety disorder (GAD) in late August 2026. This is a highly consequential clinical trial readout for a psychedelic-based therapy (lysergide tartrate) and directly relates to our active GAD watches. I will use a durable slug.

I will now update the existing note on Scholar Rock's apitegromab (`scholar-rock-apitegromab-sma-manufacturing-update`) to incorporate the massive developments that occurred in late August and early September 2026: 1. On August 24, 2026, Scholar Rock withdrew its European Marketing Authorisation Application (MAA) for apitegromab in SMA because the Catalent Indiana site (which was the only fill-finish site in the European application) received an adverse Official Action Indicated (OAI) FDA classification. 2. Meanwhile, its U.S. BLA remains fully on track for its September 30, 2026 PDUFA date because they had a second, independent U.S.-based fill-finish site and successfully removed Catalent Indiana from the U.S. BLA. 3. On September 2, 2026, Scholar Rock announced that the FDA granted Fast Track and Orphan Drug designations to apitegromab for its second program in Facioscapulohumeral Muscular Dystrophy (FSHD), as participant dosing commenced in the Phase 2 FORGE trial. Let's write the updated note body.

I will now write a note for Capricor's deramiocel BLA extension. The FDA extended the PDUFA target action date for deramiocel in Duchenne muscular dystrophy (DMD) by three months, from August 22, 2026 to November 22, 2026. This was classified as a major amendment after Capricor submitted 24-month open-label extension data from the Phase 3 HOPE-3 study to support a refined proposed indication focused on upper limb function (following a negative 9-3 Advisory Committee vote in July 2026). Let's see if we have an existing note on this. Yes! The preview list includes: - `capricor-deramiocel-dmd-cardiomyopathy-fda-review` (or similar, wait, let's look at the exact slugs in the retrieved notes): The notes retrieved: - `capricor-deramiocel-dmd-cardiomyopathy-fda-review` (preview: "In a major setback for Capricor Therapeutics, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 9 to 3 on July 29, 2026, against recommending...") - `capricor-deramiocel-dmd-cardiomyopathy-fda-adcomm-vote` (preview: "In a major setback for Capricor Therapeutics, the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) voted 9 to 3 on July 29, 2026, against recommending...") Wait, the two are near-synonyms. Let's reuse `capricor-deramiocel-dmd-cardiomyopathy-fda-review` to update it with this major new regulatory extension. I will write the updated note body.

Let's check if there are other threads we can resolve or record events for. Let's review the active threads: 1. `FDA clinical hold status on REGENXBIO's RGX-121` (id: `01a059fd-bad5-7ea0-bd1b-3a989909eea5`). The trigger is: "Fires when the FDA formally lifts the clinical hold or takes further regulatory action on RGX-121." On August 24, 2026, the FDA placed a clinical hold on REGENXBIO's IND for the Phase I/II/III trial of RGX-121 following the discovery of asymptomatic spine MRI findings (nodules/masses) in five participants. This is a massive "further regulatory action" that halts the program and delays the BLA resubmission indefinitely. Let's call `record_event` on this thread and resolve it. Wait, let's look at the parameters for `record_event`: - `thread_id`: `01a059fd-bad5-7ea0-bd1b-3a989909eea5` - `cycle_id`: `22b596f2-cd4a-4f1a-a133-4186a8ada4ed` - `summary`: `FDA formally places a new clinical hold on REGENXBIO's RGX-121 IND over spine MRI findings, delaying near-term BLA resubmission.` - `outcome`: `The FDA placed a clinical hold on the IND for RGX-121 on August 24, 2026, following the discovery of asymptomatic spine MRI findings in five participants. REGENXBIO announced that it no longer expects to resubmit the BLA in the near term.` - `resolves`: `true` (since this is a one-shot watch for further regulatory action/hold status update and we have a definitive hold action). - `salience`: `5` (very high salience for this rare-disease gene therapy program). Let's do this first.

Now I will call `resolve_thread` for the REGENXBIO RGX-121 hold thread. Wait, let's look at the parameters for `resolve_thread`: - `thread_id`: `01a059fd-bad5-7ea0-bd1b-3a989909eea5` - `cycle_id`: `22b596f2-cd4a-4f1a-a133-4186a8ada4ed` - `resolution_note`: `The FDA formally placed a new clinical hold on the IND for RGX-121 on August 24, 2026, following the discovery of asymptomatic spine MRI findings in five participants. REGENXBIO has suspended its near-term BLA resubmission plans.` Let's call `resolve_thread` for this.

Now let's look at the uniQure watch/thread: - `uniQure BLA submission for AMT-130 in Huntington's disease` (id: `019ed7c8-8ce2-7ba0-9576-f823526d0677`). Trigger: "uniQure". Description: "Monitor uniQure's formal submission of the BLA for AMT-130 in Huntington's disease, targeted for Q3 2026." On September 2, 2026, uniQure formally announced the submission of its BLA to the FDA for the accelerated approval of AMT-130 in Huntington's disease. This is a perfect match and directly resolves the thread! Let's call `record_event` on it: - `thread_id`: `019ed7c8-8ce2-7ba0-9576-f823526d0677` - `cycle_id`: `22b596f2-cd4a-4f1a-a133-4186a8ada4ed` - `summary`: `uniQure formally submits BLA to FDA for AMT-130 in Huntington's disease on September 2, 2026.` - `outcome`: `uniQure submitted its BLA for accelerated approval of AMT-130 in Huntington's disease on September 2, 2026, supported by three-year clinical data from its Phase I/II study.` - `resolves`: `true` - `salience`: `5` (very high salience for the first-ever gene therapy BLA for Huntington's disease).

Now I will call `resolve_thread` for the uniQure AMT-130 thread: - `thread_id`: `019ed7c8-8ce2-7ba0-9576-f823526d0677` - `cycle_id`: `22b596f2-cd4a-4f1a-a133-4186a8ada4ed` - `resolution_note`: `uniQure formally submitted its BLA to the FDA for accelerated approval of AMT-130 in Huntington's disease on September 2, 2026, supported by three-year data showing a slowing of disease progression.` Let's call `resolve_thread` for this.

Now let's check if there are any other watches we can resolve or update. What about the watch: `Definium Phase 3 Panorama trial readout of DT120 in GAD` (id: `01a0079b-2493-7ec5-b616-680631330a60`). The fire date is September 30, 2026. The trigger is: "Fires when Definium reports topline Phase 3 Panorama results." And `Definium DT120 Phase 3 GAD and low-dose MDD trial readouts` (id: `019f1ab9-37ce-758f-a72b-8d16fad8f514`). Wait, the Voyage trial readout occurred in late August 2026, but the Panorama trial readout is still expected in September 2026 (or "late September 2026"). Since Panorama hasn't read out yet, these watches remain open. What about: `FDA regulatory decision on Capricor's deramiocel BLA in DMD` (id: `01a04a8a-ef03-71c2-b52d-92704685603b`). Wait! The watch description is: "Monitor the FDA's final regulatory decision on Capricor's Biologics License Application (BLA) for deramiocel in Duchenne muscular dystrophy (DMD) on or before its new extended PDUFA date of November 22, 2026." Wait, the PDUFA date was extended on August 24, 2026, and the watch title and description already reflect the new extended PDUFA date of November 22, 2026 (someone must have updated it or created it with the new date, or it was updated in a prior step). Since the final regulatory decision (approval or CRL) has not occurred yet, this watch remains active and open. Let's check if there are any other watches that we should register. We have some brand new approvals: 1. **Lisraya (brepocitinib)** for dermatomyositis (approved August 27, 2026). 2. **Mimrylo (rusfertide)** for polycythemia vera (approved August 28, 2026). Wait, since these are approved, are there any future catalysts to watch for? Maybe the commercial launch or upcoming clinical trials, but typically approvals don't require an ongoing watch unless there is a specific post-marketing commitment or subsequent trial readout. Wait, let's see: Takeda is continuing the open-label extension of the VERIFY trial for Mimrylo. And Roivant is developing brepocitinib for other indications, but dermatomyositis is now approved. What about uniQure's BLA for AMT-130? Since uniQure submitted the BLA on September 2, 2026, we should register a watch for the FDA's regulatory decision (approval or CRL) on the BLA! Let's see: the priority review decision is expected by the end of November 2026 (which would set a PDUFA date around Q2 2027). Let's register a watch for the FDA's final regulatory decision on uniQure's AMT-130 BLA for Huntington's disease. - `title`: `FDA regulatory decision on uniQure's AMT-130 BLA in Huntington's disease` - `watch_type`: `live_process` or `dated_catalyst` (since PDUFA date is not allocated yet, let's use `live_process` or set a tentative date around May 2027). Let's use `live_process` with cardinality `one_shot`. - `description`: `Monitor the FDA's final regulatory decision (approval or complete response letter) on uniQure's Biologics License Application (BLA) for AMT-130 in Huntington's disease.` - `entity`: `uniQure / FDA` - `note`: `Fires when the FDA grants accelerated approval or issues a Complete Response Letter (CRL) for AMT-130 in Huntington's disease.` Let's register this watch.

Excellent. Now let's register a watch for the FDA's regulatory decision on Scholar Rock's apitegromab BLA in SMA, which has a PDUFA date of September 30, 2026. Wait, we already have a watch for that: `FDA regulatory decision on Scholar Rock's apitegromab BLA in SMA` (id: `01a030ca-8bbc-74d9-aad8-2f305e2757e3`). Let's see if there are any other watches we should register. What about the FDA regulatory decision on Karyopharm's supplemental NDA for XPOVIO (selinexor) plus ruxolitinib in myelofibrosis? The search results showed: "Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis" on August 31, 2026. And: "Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE849 monotherapy by year-end 2026 in ES-SCLC..." (IDEAYA Biosciences). These are interesting, but maybe not as high-priority as the major ones. Wait, let's verify if there is any other major news we missed. Let's review our findings: 1. **Roivant's Lisraya (brepocitinib)** approved for dermatomyositis on August 27, 2026. (First oral, first targeted therapy for DM). 2. **Takeda's Mimrylo (rusfertide)** approved for polycythemia vera on August 28, 2026. (First-in-class hepcidin mimetic, reduces phlebotomy burden). 3. **uniQure's AMT-130** BLA submitted for Huntington's disease on September 2, 2026. (First gene therapy BLA for HD, resolving a watch). 4. **Definium's DT120** reported positive Phase 3 Voyage results in GAD in late August 2026. (First of two GAD Phase 3 trials, showing strong Cohen's d of 0.81). 5. **Scholar Rock's apitegromab** updated with EU MAA withdrawal on August 24, 2026, and FSHD Fast Track designation on September 2, 2026. 6. **Capricor's deramiocel** updated with FDA's 3-month PDUFA extension to November 22, 2026, following a major amendment. This is a phenomenal and highly comprehensive set of updates! Each finding is highly consequential, grounded in primary sources, and carries verbatim quotes and links. Let's call `finish_cycle` to end this highly successful research cycle.

I have successfully completed this research cycle, surfacing several highly consequential science, health, and policy developments, resolving two active watches, and updating several ongoing clinical and regulatory tracks. ### Key Developments Surfaced This Cycle 1. **Historic First-in-Class FDA Approvals:** * **Lisraya (brepocitinib) for Dermatomyositis (Approved Aug 27, 2026):** Roivant and Priovant secured the first-ever targeted and first-ever oral therapy approval for adults with dermatomyositis, backed by the landmark Phase 3 VALOR trial (the largest trial ever conducted in this rare disease). * **Mimrylo (rusfertide) for Polycythemia Vera (Approved Aug 28, 2026):** Takeda and Protagonist Therapeutics won approval for the first-in-class hepcidin mimetic, providing a highly effective weekly subcutaneous alternative to therapeutic phlebotomy (bloodletting) for hematocrit control in adults with PV. 2. **Major Gene Therapy Regulatory Milestones (Resolved Watches):** * **uniQure Submits AMT-130 BLA for Huntington's Disease (Submitted Sept 2, 2026):** uniQure formally submitted its BLA to the FDA for accelerated approval of AMT-130, marking the first-ever gene therapy BLA in Huntington's disease. This directly resolved the active watch **`uniQure BLA submission for AMT-130 in Huntington's disease`**. * **FDA Places New Clinical Hold on REGENXBIO's RGX-121 (Announced Aug 24, 2026):** The FDA formally placed a clinical hold on the IND for RGX-121 following asymptomatic spine MRI findings in five participants, derailing near-term BLA resubmission plans. This directly resolved the active watch **`FDA clinical hold status on REGENXBIO's RGX-121`**. 3. **Breakthrough Psychiatric Trial Readouts:** * **Definium's DT120 Lysergide ODT Succeeds in Phase 3 GAD (Late Aug 2026):** Definium Therapeutics reported positive topline results from its Phase 3 Voyage trial in generalized anxiety disorder (GAD). The drug demonstrated a massive, placebo-adjusted HAM-A reduction of -5.4 points (Cohen's d = 0.81), more than double the effect size of standard GAD therapies, with a highly manageable 6.4-hour session clearance profile. 4. **Critical Regulatory Adjustments and Pipeline Expansions:** * **Scholar Rock Withdraws European MAA for Apitegromab / Gains FSHD Fast Track:** Following an adverse FDA inspection classification (OAI) at Catalent Indiana, Scholar Rock withdrew its European application on August 24, 2026. However, its U.S. BLA remains fully on track for its September 30, 2026 PDUFA date utilizing an alternate fill-finish site. Additionally, on September 2, 2026, the FDA granted Fast Track and Orphan Drug designations to apitegromab in FSHD as Phase 2 FORGE dosing commenced. * **Capricor Secures 3-Month BLA Extension for Deramiocel (New PDUFA Nov 22, 2026):** Following a negative 9-3 advisory committee vote in July, Capricor submitted a major amendment (including 24-month open-label extension data) to narrow its proposed indication to upper limb function, prompting the FDA to extend the review timeline to November 22, 2026.